<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00481572</url>
  </required_header>
  <id_info>
    <org_study_id>1124</org_study_id>
    <nct_id>NCT00481572</nct_id>
  </id_info>
  <brief_title>Continuous Infusion of Terlipressin in Septic Shock</brief_title>
  <official_title>Continuous Terlipressin Versus Vasopressin Infusion in Septic Shock. A Randomized, Controlled, Pilot Trial. &quot;THE TERLIVAP STUDY&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether: A)the continuous infusion ultra-low dose
      of terlipressin (1.3 micrograms/kg/h) is able to stabilize hemodynamic in patients with
      septic shock, reducing the risk of adverse effects related to the bolus dose.B)the continuous
      infusion ultra-low dose of terlipressin may be use in lieu of vasopressin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Forty-five septic shock patients requiring vasopressor support to maintain mean arterial
      pressure between 65 and 75 mmHg despite adequate volume resuscitation were enrolled in the
      study. Patients were randomly allocated to be treated with either a) a continuous
      terlipressin infusion (1.3 µg•kg-1), b) vasopressin (0.03 U•min-1), or c) titrated
      norepinephrine (control; each n = 15). In both the terlipressin and vasopressin group,
      norepinephrine was additionally administered to achieve a mean arterial pressure (MAP)
      between 65 and 75 mmHg, if necessary. Data from right heart catheterization, thermo-dye
      dilution catheter, gastric tonometry as well as data from organ function, cytokines
      concentrations, were obtained at baseline and after 12, 24, 36 and 48 hours.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systemic and regional hemodynamics</measure>
    <time_frame>during the first 48 hours from the onset of septic shock</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Markers of inflammation,organ functions,adverse effects.</measure>
    <time_frame>during the first 48 hours from the onset of septic shock</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Terlipressin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vasopressin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>titrated norepinephrine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin</intervention_name>
    <description>continuous terlipressin infusion 1.3 µg•kg-1 over a period of 48 hrs</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vasopressin</intervention_name>
    <description>continuous intravenous infusion of vasopressin 0.03 U•min-1 over a period of 48 hrs</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine</intervention_name>
    <description>titrated norepinephrine over a period of 48 hrs</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Septic shock

          -  vasopressor support to maintain mean arterial pressure (MAP) between 65 and 75 mmHg
             despite adequate volume resuscitation (pulmonary artery occlusion pressure = 13-18
             mmHg and central venous pressure = 8-12 mmHg)

        Exclusion Criteria:

          -  Pregnancy

          -  Present cardiac dysfunction

          -  Present or suspected acute mesenteric ischemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Morelli, MD</last_name>
    <role>Study Director</role>
    <affiliation>Departement of Anesthesiology and Intensive Care of the University of Rome &quot;La Sapienza&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Anesthesiology and Intensive care of the University of Rome &quot;La Sapienza&quot;</name>
      <address>
        <city>Rome, Viale del Policlinico 155</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2007</study_first_submitted>
  <study_first_submitted_qc>May 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2007</study_first_posted>
  <last_update_submitted>February 26, 2008</last_update_submitted>
  <last_update_submitted_qc>February 26, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>Andrea Morelli</name_title>
    <organization>University of Roma &quot;La Sapienza&quot;</organization>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>Septic Shock</keyword>
  <keyword>vasopressin</keyword>
  <keyword>terlipressin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Terlipressin</mesh_term>
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
    <mesh_term>Lypressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

